Find Clinical Trials

Answer each question to find trials that best match your clinical situation. You can leave questions blank if you do not know the answer.

This search will output a list of trials for which you may be eligible based on the criteria you enter.

I want to enter information about my cancer and treatments

Matching Trials

For more detailed information please click on the clinical trial number and you will be taken to the clinicaltrials.gov website.
For a key to the icons and text used in the Results column, please click here.
To learn more about our trial annotation process, results assignments, and the criteria used to highlight drugs with promising results, please click here.

  Clinical Trial Phase Eligible Participant Official Title Location Drugs in Trial Results
NCT01851369IIGranulosa cell ovarian cancerA Phase I/II Trial of TRC102 (Methoxyamine HCl) in Combination With Temozolomide in Patients With Relapsed Solid Tumors and LymphomasMDView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
MethoxyamineTRC102Base excision repair inhibitorClinical Trials
TemozolomideTemodal, Temodar, MethazolastoneDNA damaging agentApproved in Other Cancers
NCT03428802IIAdvanced solid tumors with high MSI and with POLE, POLD, or BRCA1/2 mutationsA Basket Trial of Pembrolizumab in Patients With Advanced Solid Tumors and Genomic InstabilityNJ, NYView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT03462342IIPlatinum sensitive high grade serous ovarian cancer (cohort A), or platinum sensitive high grade serous ovarian cancer with BRCA1/2 mutations or HRD+ w/ clinical benefit of PARPi therapy followed by progression in most recent prior regimen (cohort DII)Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD 6738 and Olaparib in Recurrent Ovarian CancerMD, MA, PAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CeralasertibATR kinase inhibitor AZD6738, AZD6738ATR kinase inhibitorClinical Trials
OlaparibLynparza, AZD2281PARP inhibitorApproved in Ovarian Cancer
NCT03579316IIPlatinum sensitive ovarian cancer with BRCA1/2 mutations or HRD+ that must have benefited from and then progressed on prior PARP inhibitorEFFORT: Efficacy of AZD1775 in Parp Resistance; A Randomized 2-Arm, Non-Comparative Phase 2 Study of AZD1775 Alone or AZD1775 and Olaparib in Women With Ovarian Cancer Who Have Progressed During PARP InhibitionMA, TXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CeralasertibATR kinase inhibitor AZD6738, AZD6738ATR kinase inhibitorClinical Trials
OlaparibLynparza, AZD2281PARP inhibitorApproved in Ovarian Cancer
NCT03682289IIAdvanced solid tumors with ARID1A or ATM alterationsPhase II Trial of Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Selected Solid Tumor MalignanciesCAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CeralasertibATR kinase inhibitor AZD6738, AZD6738ATR kinase inhibitorClinical Trials
OlaparibLynparza, AZD2281PARP inhibitorApproved in Ovarian Cancer
NCT03693014IIAdvanced solid tumors with dMMR, high TMB or high MSI with limited progression on checkpoint inhibitor treatmentA Phase II Trial of Hypofractionated Radiotherapy in Patients With Limited Progression on Immune Checkpoint BlockadeCT, NJ, NY, PAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AtezolizumabTecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446Blocks PD-L1 inhibition of T cellsApproved in Other Cancers
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cellsApproved in Other Cancers
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
Radiation TherapyIrradiation, Radiotherapy
NCT03732950IIRecurrent ovarian cancerA Phase II Study of Pembrolizumab Monotherapy in Recurrent Ovarian Cancer of the Immunoreactive Subtype Determined by NanoString Gene Expression ProfilingCA, MNView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT03734692IIPlatinum sensitive ovarian cancer with first or second recurrence in peritoneal cavitySystemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian CancerPAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CisplatinCACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, PlatosinDNA damaging agentApproved in Ovarian Cancer
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
RintatolimodAtvogenTLR3 agonist and immune cell stimulatorApproved in Other Indications
NCT03878849IIRecurrent ovarian cancerPhase II, Prospective Open Label, Single Arm Study to Investigate Anti-tumor Effect and Tolerability of 2X-121 in Patients With Advanced Ovarian Cancer Selected by the 2X-121 DRP®OK, WAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
StenoparibPARP/Tankyrase inhibitor 2X-121, E7449, 2X-121PARP inhibitorClinical Trials
NCT03911557IIAdvanced solid tumors with moderate/high TMBPhase 2 Investigation of MEDI4736 (Durvalumab) and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid TumorsKYView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
DurvalumabAnti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, ImfinziBlocks PD-L1 inhibition of T cellsApproved in Other Cancers
TremelimumabTicilimumab, CP-675206, CP-675,206, CP-675, anti-CTLA4 human monoclonal antibody CP-675,206Blocks CTLA-4 inhibition of T cellsApproved in Other Cancers
NCT03907475IIAdvanced solid tumors (with tumor amenable to skin biopsy)DURVA+ : Evaluation of the Safety and Pharmacodynamics of Anti-PD-L1 Antibody Durvalumab in Combination With Chemotherapy in Patients With Advanced Solid TumorsMDView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CapecitabineCAPE, XelodaRNA processing and thymidylate synthase inhibitorNCCN Guidelines for Ovarian Cancer
CarboplatinParaplatin, NovoplatinumDNA damaging agentApproved in Ovarian Cancer
DurvalumabAnti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, ImfinziBlocks PD-L1 inhibition of T cellsApproved in Other Cancers
GemcitabineGemzarRibonucleotide reductase and DNA synthesis inhibitorApproved in Ovarian Cancer
Liposomal doxorubicinPegylated Liposomal Doxorubicin Hydrochloride, liposomal doxorubicin, LipoDox, Evacet, Dox-SL, DoxilTopoisomerase II inhibitorApproved in Ovarian Cancer
nab-PaclitaxelPaclitaxel Albumin-Stabilized Nanoparticle Formula, Abraxane, ABI-007Microtubule stabilizer/mitotic inhibitorNCCN Guidelines for Ovarian Cancer
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitorApproved in Ovarian Cancer
NCT02710253IIAdvanced solid tumors that must have progressed on prior immunotherapy or cellular therapy (amenable to radiation therapy)Phase II Trial of Salvage Radiation Therapy to Induce Systemic Disease Regression After Progression on Systemic ImmunotherapyTXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Radiation TherapyIrradiation, Radiotherapy
NCT03994796IIAdvanced solid tumors with brain metastases and NTRK, ROS1, KRAS G12C, CDK pathway or PI3K pathway alterationsGenomically-Guided Treatment Trial in Brain MetastasesAK, AZ, AR, CA, CO, CT, FL, GA, ID, IL, IA, KS, KY, LA, MA, MI, MN, MS, MO, MT, NE, NH, NJ, NY, NC, OH, OK, OR, PA, TX, UT, VT, VA, WA, WI, WYView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AbemaciclibBemaciclib, LY2853219, CDK4/6 Dual Inhibitor LY2835219, VerzenioCDK4/6 inhibitorApproved in Other Cancers
AdagrasibKRAS G12C inhibitor MRTX849, MRTX849KRAS G12C inhibitorApproved in Other Cancers
EntrectinibRXDX-101, TrkA/B/C/ROS1/ALK tyrosine kinase inhibitor RXDX-101, RozlytrekALK, TRK, ROS1 kinase inhibitorApproved in Other Cancers
PaxalisibGDC-0084, PI3K inhibitor GDC-0084, RG7666PI3K/mTOR inhibitorClinical Trials
NCT04449549IIRecurrent rare tumorsRapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and PaclitaxelMDView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
NilotinibAMN 107, TasignaBcr-abl, c-Kit, and PDGFR kinase inhibitorApproved in Other Cancers
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitorApproved in Ovarian Cancer
NCT04469764IIRecurrent ovarian cancer with CCND1-3 or CDK4/6 amplifications or CDKN2A alterationsAn Open Label Phase II Study of the Efficacy and Safety of Abemaciclib, a Cyclin Dependent Kinase (CDK4/6) Inhibitor in Selected Patients With Recurrent Ovarian or Endometrial CancerCAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AbemaciclibBemaciclib, LY2853219, CDK4/6 Dual Inhibitor LY2835219, VerzenioCDK4/6 inhibitorApproved in Other Cancers
AnastrozoleArimidexAromatase inhibitor
LetrozoleFemaraAromatase inhibitorNCCN Guidelines for Ovarian Cancer
NCT04534283IIAdvanced solid tumors with alterations in BRAF, RAF1, MEK1/2, ERK1/2 or NF1A Phase 2 Basket Trial of an ERK1/2 Inhibitor (LY3214996) in Combination With Abemaciclib for Patients Whose Tumors Harbor Pathogenic Alterations in BRAF, RAF1, MEK1/2, ERK1/2, and NF1.INView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AbemaciclibBemaciclib, LY2853219, CDK4/6 Dual Inhibitor LY2835219, VerzenioCDK4/6 inhibitorApproved in Other Cancers
TemuterkibLY3214996ERK inhibitorClinical Trials
NCT04550494IIAdvanced solid tumors with alterations in ARID1A, ATM, ATR, BAP1, BARD1, BRCA 1/2, BRIP1, CDK12, CHK1/2, FANCA/B/C/D2/E/F/G/I/J/L/M/N, IDH1/2, MRE11A, NBN, PALB2, RAD50/51/51B/51C/51D or RAD54L (only 1 prior platinum therapy; germ-line BRCA MUT patients must have progressed on prior PARP inhibitor)A Pharmacodynamics-Driven Trial of Talazoparib, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Aberrations in Genes Involved in DNA Damage ResponseFL, MD, OKView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
TalazoparibMDV3800, BMN-673, Talazoparib Tosylate, TalzennaPARP inhibitorApproved in Other Cancers
NCT04592653IIRecurrent ovarian cancerClinical and Immunologic Activity of Nemvaleukin Alfa With Less Frequent IV Dosing Schedule as Monotherapy and in Combination With Pembrolizumab and Impact on Tumor Microenvironment in Solid Tumor Patients - ARTISTRY-3MI, TX, UT, VAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Nemvaleukin alfaintermediate-affinity interleukin-2 receptor agonist ALKS 4230, Nemvaleukin, ALKS4230IL-2R/IL-15R beta and gamma agonistClinical Trials
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT04589845IIAdvanced solid tumors with alterations in ALK, ATM, BRAF (class III), KRAS G12C, NTRK1/2/3, PIK3CA (multiple mutations), RET, ROS1 or SETD2Tumor-Agnostic Precision Immunooncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform TrialAL, AZ, CA, CO, FL, GA, ID, MD, MI, MN, MT, NH, NJ, NM, NY, OH, PA, TN, TX, VA, WA, WIView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AlectinibAF802, anaplastic lymphoma kinase inhibitor CH5424802, Alecensa, ALK inhibitor CH5424802ALK kinase inhibitorApproved in Other Cancers
BelvarafenibHM95573BRAF kinase inhibitorClinical Trials
CamonsertibRP-3500ATR kinase inhibitorClinical Trials
DivarasibGDC-6036KRAS G12C inhibitorClinical Trials
EntrectinibRXDX-101, TrkA/B/C/ROS1/ALK tyrosine kinase inhibitor RXDX-101, RozlytrekALK, TRK, ROS1 kinase inhibitorApproved in Other Cancers
InavolisibRG6114, GDC-0077PI3K alpha inhibitorClinical Trials
PralsetinibBLU-667RET-kinase inhibitorApproved in Other Cancers
NCT04625270IIRecurrent low grade serous ovarian cancerA Phase 2 Study of Avutometinib (VS-6766) (Dual RAF/MEK Inhibitor) Alone and In Combination With Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)AZ, CA, CT, FL, IL, MD, MN, MO, NV, NM, NY, OH, OK, OR, TN, TX, VAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AvutometinibCH5126766, Raf/MEK dual kinase inhibitor RO5126766, RO5126766, CKI27, VS-6766RAF and MEK inhibitorClinical Trials
DefactinibVS-6063, PF-04554878, PF-04554878FAK inhibitorClinical Trials
NCT04739618IIAdvanced solid tumors - intratumoral injectionA Phase 2 Trial of Non-ablative Cryosurgical Freezing and Multiplex Immunotherapy in Patients With Metastatic Solid CancerAZView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cellsApproved in Other Cancers
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
ThermotherapyClinical Trials
NCT04771520IIAdvanced solid tumors with c-Kit or PDGFRA mutations (except c-KIT V654A or T670I)Phase 2 Study of Avapritinib in Patients With CKIT or PDGFRA Mutation-Positive Malignant Solid TumorsTXView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AvapritinibPDGFRa and c-Kit inhibitorApproved in Other Cancers
NCT02896335IIPatients with progressive brain metastases with amplifications in CDK4, CDK6, CCND1, CCND2, CCND3 or CCNE1 or loss of CDKN2AA Phase 2 Study of Palbociclib in Progressive Brain Metastases Harboring Alterations in the CDK PathwayMAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
PalbociclibPD-0332991, PD0332991, IbranceCDK4/6 inhibitorApproved in Other Cancers
NCT04919629IIRecurrent ovarian cancer with symptomatic ascites or pleural effusionRandomized Phase 2 Trial of APL-2 With Pembrolizumab vs. APL-2 With Pembrolizumab and Bevacizumab vs. Bevacizumab Alone in Patients With Recurrent Ovarian Cancer and Persistent Malignant EffusionNYView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Bevacizumabimmunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, AvastinVEGF antagonistApproved in Ovarian Cancer
PegcetacoplanC3-targeted complement inhibitor APL-2, APL-2Blocks the cleavage of C3Approved in Other Indications
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT04957615IIAdvanced solid tumors with ARID1A mutationsA Phase II Clinical Trial to Investigate ARID1A Mutation and CXCL13 Expression in the Pre-Treatment Tumor Samples as a Combinatorial Predictive Biomarker for Immune Checkpoint Therapy in Metastatic Solid TumorsTXView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT05064280IIAdvanced solid tumors with brain metastasesPhase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain MetastasesTXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
LenvatinibMK-7902, Lenvima, ER-203492-00, E7080Multi-targeted RTK inhibitorApproved in Other Cancers
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT05071937IIRecurrent ovarian cancer with prior PARP inhibitor (at most 4 prior chemotherapy regimens)Phase ll Study of a BET Inhibitor, ZEN003694, Combined With a PARP Inhibitor, Talazoparib, in Patients With Recurrent Ovarian CancerPAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
TalazoparibMDV3800, BMN-673, Talazoparib Tosylate, TalzennaPARP inhibitorApproved in Other Cancers
ZEN-3694ZEN003694, BET bromodomain inhibitor ZEN-3694BET inhibitorClinical Trials
NCT05082025IIRecurrent ER+ and/or PR+ ovarian cancer with alterations in PIK3CA, PIK3R1 or PTENPhase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN AlterationsTXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CopanlisibBAY 80-6946, PI3K inhibitor BAY 80-6946pan-PI3K inhibitorApproved in Other Cancers
FulvestrantZD9238, ICI 182,780, FaslodexER antagonist (SERD)Approved in Other Cancers
NCT05097599IIAdvanced solid tumors with ALK or ROS1 fusions, BRAF V600X, BRCA1/2, or gPALB2 alterations, or HER2+, Nectin-4+ or TROP2+, or IRS-H+ or Angio TRS-H+Strata PATH™ (Precision Indications for Approved Therapies): A Study Evaluating the Clinical Activity and Safety of Approved Drugs Within Biomarker-Guided Patients With Solid TumorsAR, DE, FL, IA, LA, OH, TN, WIView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AxitinibInlyta, AG-013736Multi-targeted RTK inhibitor
BinimetinibMEK162, MEK inhibitor MEK162, ARRY-162, ARRY-438162, MektoviMEK inhibitorApproved in Other Cancers
EncorafenibRaf Kinase Inhibitor LGX818, LGX818RAF inhibitorApproved in Other Cancers
Enfortumab VedotinADC: anti-Nectin-4 + microtubule destabilizer (MMAE)Approved in Other Cancers
LorlatinibPF-06463922ALK and ROS1 kinase inhibitorApproved in Other Cancers
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
Sacituzumab govitecanTrodelvy, hrS7-SN38 antibody drug conjugate, anti-TROP-2 Antibody-Drug Conjugate IMMU-132ADC: anti-TROP2 + topoisomerase I inhibitor (SN38)Approved in Other Cancers
TalazoparibMDV3800, BMN-673, Talazoparib Tosylate, TalzennaPARP inhibitorApproved in Other Cancers
Trastuzumab deruxtecanT-Dxd, DS-8201, fam-trastuzumab deruxtecan-nxki, ADC DS-8201a, anti-HER2 antibody-drug conjugate DS-8201a, anti-HER2 ADC DS-8201a, DS-8201aADC: anti-HER2 + topoisomerase I inhibitor (Dxd)Approved in Other Cancers
NCT05113368IIRecurrect low grade serous ovarian cancerEfficacy of Oral Regorafenib Combined With Intra-muscular Injection of Fulvestrant in Patients With Recurrent Low-grade Serous Ovarian Cancer: A Phase II Single Arm TrialPAView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
FulvestrantZD9238, ICI 182,780, FaslodexER antagonist (SERD)Approved in Other Cancers
RegorafanibBAY73-4506, multikinase inhibitor BAY 73-4506, StivargaMulti-targeted RTK inhibitorApproved in Other Cancers
NCT05185947IIRecurrent or persistent non-mucinous ovarian cancer with peritoneal disease (IP/IV)Phase II Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis From Colorectal, Appendiceal, Small Bowel, Gastric, Cholangiocarcinoma, Breast, Ovarian, or Other Gynecologic Primary CancerMDView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
NilotinibAMN 107, TasignaBcr-abl, c-Kit, and PDGFR kinase inhibitorApproved in Other Cancers
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitorApproved in Ovarian Cancer
NCT05199584IIAdvanced solid tumors with loss of function PTCH1 mutationsA Phase 2, Multi-Center Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function MutationsCA, FL, IL, LA, NV, NY, NC, OH, PA, TN, TX, VA, WIView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
TaladegibLY2940680, ENV-101Smoothened antagonistClinical Trials
NCT04992013IIOvarian cancer with brain metastases and alterations in ATM, ATR, BAP1, BARD1, BRCA1/2, BRIP1, MRE11A, NBN, PALB2, RAD50, RAD51B/C/D, RAD54B/L, XRCC2, or XRCC3 (with measurable disease in the CNS)Genomically Guided Phase II Study to Evaluate the Clinical Benefit of Niraparib in Tumors Metastatic to the CNSMAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
NiraparibZejula, MK4827PARP inhibitorApproved in Ovarian Cancer
NCT05231122IIRecurrent serous, endometrioid or clear cell ovarian cancerRandomized Phase 2 Clinical Trial of Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 in Patients With Recurrent Ovarian CancerNY, TXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Bevacizumabimmunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, AvastinVEGF antagonistApproved in Ovarian Cancer
CDX-1140Stimulates CD40 to increase/activate antigen-presenting cells and enhance immune responseClinical Trials
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT05286801IIAdvanced solid tumors with loss of SMARCB1 or SMARCA1A Phase 1/2 Study of Tiragolumab (NSC# 827799) and Atezolizumab (NSC# 783608) in Patients With Relapsed or Refractory SMARCB1 or SMARCA4 Deficient TumorsAL, CA, CO, DC, IL, IN, MD, MA, MI, MN, MO, NY, NC, OH, PA, TN, TX, UTView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AtezolizumabTecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446Blocks PD-L1 inhibition of T cellsApproved in Other Cancers
TiragolumabMTIG7192A, RO7092284Blocks TIGIT binding to PVR (CD155) and PVRL2 (CD112) to enable DNAM-1 (CD226) mediated activation of NK and CD8 T cellsClinical Trials
NCT05296512IIRecurrent or persistent clear cell ovarian cancer or mixed epithelial carcinoma with a clear cell componentA Phase II Trial of Pembrolizumab and Lenvatinib in Patients With Recurrent or Persistent Clear Cell Carcinoma of the OvaryMAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
LenvatinibMK-7902, Lenvima, ER-203492-00, E7080Multi-targeted RTK inhibitorApproved in Other Cancers
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT05327010IIAdvanced solid tumors with alterations in BARD1, BRCA 1/2, BRIP1, FANCA, PALB2; RAD51 or RAD51C/D with PARP inhibitor therapy as immediate prior therapy or advanced solid tumors with a KRAS G12C mutation with prior KRAS G12C targeted therapy or platinum sensitive ovarian cancer without BRCA1/2 mutations with CR/PR on prior PARP inhibitorPhase 2 Trial of the Combination of the BET Inhibitor, ZEN003694 (ZEN-3694), and the PARP Inhibitor Talazoparib, in Patients With Molecularly-Selected Solid Tumors (ComBET)CO, GA, IL, NC, PA, TXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
TalazoparibMDV3800, BMN-673, Talazoparib Tosylate, TalzennaPARP inhibitorApproved in Other Cancers
ZEN-3694ZEN003694, BET bromodomain inhibitor ZEN-3694BET inhibitorClinical Trials
NCT05337735IIAdvanced solid tumors with dMMR or high MSIA Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare CancersTXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
VudalimabXmAb717, anti-PD1/CTLA4 bispecific antibody XmAb20717, XmAb20717Blocks PD-1 and CTLA-4 inhibition of T cellsClinical Trials
NCT05489211IIAdvanced solid tumorsA Phase II, Multicentre, Open-label, Master Protocol to Evaluate the Efficacy and Safety of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination With Anticancer Agents in Patients With Advanced/Metastatic Solid TumoursCA, IN, MA, MI, NJ, NM, NY, OH, TN, TX, WIView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AZD5305PARP1 inhibitorClinical Trials
CarboplatinParaplatin, NovoplatinumDNA damaging agentApproved in Ovarian Cancer
Datopotamab deruxtecanAnti-TROP2/DXd antibody-drug conjugate DS-1062a, Dato-DXdADC: anti-TROP2 + topoisomerase I inhibitor (Dxd)Clinical Trials
NCT05512208IIRecurrent high grade serous, endometrioid or mucinous ovarian cancer with alterations in RAS, BRAF or NF1A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Plus Defactinib (FAK Inhibitor) in Recurrent Gynecological Cancers (DURAFAK)OKView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AvutometinibCH5126766, Raf/MEK dual kinase inhibitor RO5126766, RO5126766, CKI27, VS-6766RAF and MEK inhibitorClinical Trials
DefactinibVS-6063, PF-04554878, PF-04554878FAK inhibitorClinical Trials
NCT05523440IIRecurrent ovarian cancer with ARID1A mutationsPhase 2 Trial of Niraparib or Niraparib and Bevacizumab Combination in Patients With Recurrent Endometrial Cancer and/or Ovarian Cancer With ARID1A Mutation (OU-SCC-ARID1A)OKView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Bevacizumabimmunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, AvastinVEGF antagonistApproved in Ovarian Cancer
NiraparibZejula, MK4827PARP inhibitorApproved in Ovarian Cancer
NCT05554341IIAdvanced solid tumors with prior taxane therapyNilotinib and Paclitaxel in Patients With Prior Taxane-Treated Solid Tumors: A ComboMATCH Treatment TrialAL, CA, IL, KY, LA, MD, MI, MO, NV, NY, OH, OK, TX, WA, WIView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
NilotinibAMN 107, TasignaBcr-abl, c-Kit, and PDGFR kinase inhibitorApproved in Other Cancers
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitorApproved in Ovarian Cancer
NCT05503797IIAdvanced solid cancers with a BRAF fusionA Phase 2 Master Protocol to Assess the Efficacy and Safety of FORE8394, an Inhibitor of BRAF Class 1 and Class 2 Alterations, in Participants With Cancer Harboring BRAF AlterationsCA, FL, MD, MO, NE, OHView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Plixorafenib8394, BRAF inhibitor PLX8394, FORE8394BRAF kinase inhibitorClinical Trials
NCT05147558IIRecurrent carcinosarcomaA Phase II Trial of Pembrolizumab Plus Lenvatinib for the Treatment of Patients With Advanced Uterine and Ovarian CarcinosarcomasNJ, NYView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
LenvatinibMK-7902, Lenvima, ER-203492-00, E7080Multi-targeted RTK inhibitorApproved in Other Cancers
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT05634785IIAdvanced CD30+ nonseminomatous germ cell tumorsAdministration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Patients With CD30+ Nonseminomatous Germ Cell Tumors (NSGCT)NCView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
ATLCAR.CD30autologous CD30CAR-CD28-CD3zeta-expressing T lymphocytesImmune response against cancer expressing CD30Clinical Trials
NCT05661578IIAdvanced PD-L1+ solid tumorsA Phase II, Single-Arm, Open-Label Study Evaluating the Safety and Pharmacokinetics of the Intravenous Fixed-Dose Combination (IV FDC) of Tiragolumab and Atezolizumab in Participants With Locally Advanced, Recurrent or Metastatic Solid TumorsNE, WAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AtezolizumabTecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446Blocks PD-L1 inhibition of T cellsApproved in Other Cancers
TiragolumabMTIG7192A, RO7092284Blocks TIGIT binding to PVR (CD155) and PVRL2 (CD112) to enable DNAM-1 (CD226) mediated activation of NK and CD8 T cellsClinical Trials
NCT05673928IIAdvanced HER2+ solid tumors with brain metastasesA Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB)TXView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Trastuzumab emtansinetrastuzumab-MCC-DM1 immunoconjugate, trastuzumab-MCC-DM1 antibody-drug conjugate, trastuzumab-MCC-DM1, trastuzumab-DM1, T-DM1, Kadcyla, ado trastuzumab emtansineADC: anti-HER2 + microtubule destabilizer (DM1)Approved in Other Cancers
TucatinibIrbinitinib, ONT-380HER2 kinase inhibitorApproved in Other Cancers
NCT05700721IIAdvanced solid tumors with active brain metastases and with alterations in ATM, BRCA1/2, BRIP1, CDK12, CHEK1/2, FANCL, PALB2, RAD51, RAD51B/C/D, RAD52, or RAD54LPhase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET)TXView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
DostarlimabTSR-042, anti-PD-1 monoclonal antibody TSR-042, ANB011Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NiraparibZejula, MK4827PARP inhibitorApproved in Ovarian Cancer
NCT05798611IIAdvanced solid tumors with dMMR or high MSIA Phase II, Open-label, Multi-center, Basket Study of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy to Patients With Biologically Selected Advanced or Metastatic Solid Tumors (ARTIST)MA, NY, OK, PA, RIView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
ART0380ATR kinase inhibitorClinical Trials
NCT05032040IIPlatinum resistant high grade serous or recurrent clear cell ovarian cancer (at most 2 prior chemotherapy regimens)A Phase 2 Study of XmAb20717 in Patients With Selected Gynecological Malignancies and High-Risk Metastatic Castration-Resistant Prostate CancerCA, GA, MI, NV, NY, PAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
VudalimabXmAb717, anti-PD1/CTLA4 bispecific antibody XmAb20717, XmAb20717Blocks PD-1 and CTLA-4 inhibition of T cellsClinical Trials
NCT04332653Ib/IIaAdvanced solid tumors (Phase II)An Open-label Phase 1b/2a Study of NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Subjects With Relapsed/Refractory Advanced Solid TumorsFL, MI, MO, NC, PA, TN, TXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Efineptakin alfaNT-I7, GX-I7, Hyleukin, recombinant human IL-7-hybrid Fc NT-I7, TJ107IL-7R agonistClinical Trials
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT05700669Ib/IIRecurrent ovarian cancerA Phase 1b/2 Basket Study To Assess The Safety And Efficacy Of AsiDNA™ In Combination With Olaparib In Participants With Recurrent Solid TumorsTXView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AsiDNADNA repair inhibiting oligonucleotideDNA Repair decoyClinical Trials
OlaparibLynparza, AZD2281PARP inhibitorApproved in Ovarian Cancer
NCT03872947IbRecurrent ovarian cancerA Phase 1b, Multicenter Study to Determine the Dose, Safety, Efficacy and Pharmacokinetics of TRK-950 When Used in Combinations With Selected Anti-Cancer Treatment Regimens in Patients With Selected Advanced Solid TumorsAZ, CA, LA, NJ, NY, OR, TX, VA, WIView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Bevacizumabimmunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, AvastinVEGF antagonistApproved in Ovarian Cancer
CarboplatinParaplatin, NovoplatinumDNA damaging agentApproved in Ovarian Cancer
GemcitabineGemzarRibonucleotide reductase and DNA synthesis inhibitorApproved in Ovarian Cancer
Liposomal doxorubicinPegylated Liposomal Doxorubicin Hydrochloride, liposomal doxorubicin, LipoDox, Evacet, Dox-SL, DoxilTopoisomerase II inhibitorApproved in Ovarian Cancer
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
TopotecanHycamptamine, Hycamtin, TOPOTopoisomerase I inhibitorApproved in Ovarian Cancer
TRK-950monoclonal antibody TRK-950Undisclosed mechanismClinical Trials
NCT03842228IbAdvanced solid tumors with alterations in BARD1, BRCA1/2, BRIP1, FANCA, NBN, PALB2, PIK3CA (E542, E545 or H1047), PTEN, RAD51, RAD51B/C/D (in expansion)A Phase 1b Biomarker-Driven Combination Trial of Copanlisib, Olaparib, and Durvalumab (MEDI4736) in Patients With Advanced Solid TumorsCA, CO, IL, MA, OH, PA, TX, WIView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CopanlisibBAY 80-6946, PI3K inhibitor BAY 80-6946pan-PI3K inhibitorApproved in Other Cancers
DurvalumabAnti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, ImfinziBlocks PD-L1 inhibition of T cellsApproved in Other Cancers
OlaparibLynparza, AZD2281PARP inhibitorApproved in Ovarian Cancer
NCT04130516I/IIaAdvanced solid tumors with prior PD-1/PD-L1 inhibitor therapy (Phase II)A Multicenter Phase 1-2A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of LNS8801 in Patients With Advanced Cancer With and Without PembrolizumabCA, CT, MA, NM, NY, PA, TXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
LNS8801G protein-coupled estrogen receptor agonist LNS8801GPER agonistClinical Trials
NCT02484404I/IIRecurrent ovarian cancer (Phase II)Phase I/II Study of the Anti-Programmed Death Ligand-1 Antibody Durvalumab (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal CancersMDView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CediranibRecentin, Cediranib maleate, AZD2171VEGFR1-3 kinase inhibitor
DurvalumabAnti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, ImfinziBlocks PD-L1 inhibition of T cellsApproved in Other Cancers
OlaparibLynparza, AZD2281PARP inhibitorApproved in Ovarian Cancer
NCT03400332I/IIAdvanced solid tumors (Phase II)A Phase 1/2 Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced CancersAR, CA, GA, MD, MA, NE, NJ, UT, VAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
HuMax-IL8MDX 018, anti-IL-8 monoclonal antibody HuMax-IL8, BMS-986253IL-8 antagonistClinical Trials
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cellsApproved in Other Cancers
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT03157128I/IIAdvanced solid tumors with RET alterations (Phase II)A Phase 1/2 Study of Oral Selpercatinib (LOXO-292) in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001)AZ, CA, CO, CT, FL, GA, IL, LA, MD, MA, MI, MN, MO, NV, NY, NC, OH, OR, PA, TN, TX, UT, VA, WIView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
SelpercatinibLOXO-292, RET kinase inhibitor LOXO-292, RetevmoRET-kinase inhibitorApproved in Other Cancers
NCT03767348I/IIAdvanced solid tumor with high MSI or dMMR who have progressed on prior PD-1/PD-L1 inhibitor therapy - intratumoral injection (Phase II)An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination With PD1 Blockade in Patients With Solid TumorsAZ, AR, CA, FL, IA, KY, MN, NJ, NY, NC, OH, SC, TN, TX, UT, WAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
RP1oncolytic virus RP1, A genetically modified oncolytic viral strain of the herpes simplex type 1 (HSV-1) virusInduces immune response and tumor cell lysisClinical Trials
NCT03907852I/IIAdvanced mesothelin+ solid tumors (Phase II)A Phase 1/2 Single Arm Open-Label Clinical Trial of Gavocabtagene Autoleucel (Gavo-cel) in Patients With Advanced Mesothelin-Expressing CancerCA, FL, IL, MD, NY, NC, PA, TN, TXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CyclophosphamideSendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, CiclofosfamidaDNA damaging agentApproved in Ovarian Cancer
FludarabineFludara Oral, 2-F-ara-AMP, BeneflurDNA synthesis inhibitorApproved in Other Cancers
Gavocabtagene autoleucelTC-210 T cells, TC-210 TruC-T cells, autologous anti-mesothelin T-cell receptor fusion construct T cells TC-210Immune response against cancer expressing mesothelinClinical Trials
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cellsApproved in Other Cancers
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT04143711I/IIAdvanced solid tumors with ERBB2 AMP (Phase II)A Phase I/II, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF1001 in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected IndicationsCA, KS, LA, MD, NY, OH, PA, RI, TN, TX, WA, WIView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
DF1001HER2 tri-specific natural killer cell engager DF1001Re-directs NK cells and macrophages to attack HER2+ tumor cellsClinical Trials
nab-PaclitaxelPaclitaxel Albumin-Stabilized Nanoparticle Formula, Abraxane, ABI-007Microtubule stabilizer/mitotic inhibitorNCCN Guidelines for Ovarian Cancer
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT04084366I/IIAdvanced Globo H+ solid tumors (Phase II)A Phase 1/2, Open-Label, Dose-Escalation and Cohort-Expansion Study Evaluating the Safety, Pharmacokinetics, and Therapeutic Activity of OBI-999 in Patients With Advanced Solid TumorsCA, NY, TN, TXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
OBI-999anti-globo H/MMAE antibody-drug conjugate OBI 999ADC: anti-Globo H + microtubule destabilizer (MMAE)Clinical Trials
NCT03093116I/IIAdvanced solid tumors with ALK, ROS1 or NTRK1-3 alterations (Phase II)A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)CA, CO, DC, FL, GA, IL, MD, MA, MI, MN, MO, NJ, NY, NC, OH, PA, TN, TX, VA, WA, WIView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
RepotrectinibALK/ROS1/NTRK/SRC multi-kinase inhibitor TPX-0005, TPX-0005ALK, ROS1, NTRK1-3, SRC and FAK kinase inhibitorClinical Trials
NCT03175224I/IIAdvanced solid tumors with MET amplifications or MET gene fusions (Phase II)Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid TumorsAZ, CA, DE, FL, MD, MA, MN, MO, NC, OH, PA, SC, TN, TX, UT, WV, WIView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
BozitinibAPL-101, CBT-101, Vebreltinibc-Met kinase inhibitorClinical Trials
NCT04590326I/IIRecurrent ovarian cancerPhase 1/2 Study of REGN5668 (MUC16xCD28, a Costimulatory Bispecific) Administered in Combination With Cemiplimab or REGN4018 (MUC16xCD3)CA, FL, IL, MA, MI, NY, OH, WAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Cemiplimabanti-PD-1 monoclonal antibody REGN2810, REGN2810, LibtayoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
REGN5668Stimulates CD28 to increase T cell activation and immune response against MUC16 (CA125) expressing tumor cellsClinical Trials
Ubamatamabanti-MUC16/CD3 bispecific antibody REGN4018, REGN4018Re-directs T cells to attack MUC16 (CA125)+ tumor cellsClinical Trials
NCT04243499I/IIRecurrent ovarian cancer with high levels of γ9δ2 T cellsA First-in-human, Two-part Clinical Study to Assess the Safety, Tolerability and Activity of IV Doses of ICT01 as Monotherapy and in Combination With a Checkpoint Inhibitor, in Patients With Advanced-stage, Relapsed/Refractory CancerCTView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
ICT01Activates gamma/delta T cells to stimulate immune responseClinical Trials
NCT04875806I/IIAdvanced B7-H4+ solid tumors (in ovarian expansion)A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid TumorsCT, IL, NJ, NY, PA, VAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
NC762Blocks B7H4 inhibition of T cellsClinical Trials
NCT05118789I/IIAdvanced solid tumors with ROS1 rearrangement (Phase II)A Phase 1/2 Study of the Highly Selective ROS1 Inhibitor NVL-520 in Patients With Advanced NSCLC and Other Solid Tumors (ARROS-1)CA, CO, DC, FL, MA, MI, NY, NC, PA, TN, TX, VA, WAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
NVL-520ROS1 kinase inhibitorClinical Trials
NCT05262530I/IIRecurrent CLDN6+ ovarian cancerFirst-in-human, Open-label, Multicenter, Phase I/IIa, Dose Escalation Trial With Expansion Cohorts to Evaluate Safety and Preliminary Efficacy of BNT142 in Patients With CLDN6-positive Advanced Solid TumorsIN, MD, NY, NC, PA, TX, VAView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
BNT142BNT142 RiboMab (mRNA-encoded antibody)Re-directs T cells to attack CLDN6+ tumor cellsClinical Trials
NCT03190941I/IIAdvanced solid tumors with a RAS G12V mutationA Phase I/II Study Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 PatientsMDView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AldesleukinIL-2R agonistApproved in Other Cancers
Anti-KRAS G12V mTCR PBLImmune response against cancer expressing RAS G12VClinical Trials
CyclophosphamideSendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, CiclofosfamidaDNA damaging agentApproved in Ovarian Cancer
FludarabineFludara Oral, 2-F-ara-AMP, BeneflurDNA synthesis inhibitorApproved in Other Cancers
NCT04528836I/IbAdvanced solid tumors with a KRAS G12C mutation or NF1 loss of function mutations (in expansion)A Phase 1/1B First-in-Human Study of the SHP2 Inhibitor BBP-398 (Formerly Known as IACS-15509) in Patients With Advanced Solid TumorsAL, CA, CO, TX, UT, VA, WAView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
BBP-398IACS-15509SHP2 inhibitorClinical Trials
NCT02264678IPlatinum sensitive ovarian cancer with BRCA1/2, PALB2 or RAD51C/D mutations, or HRD+ that must have progressed on PARP inhibitor, no prior ATR inhibitorA Modular Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ceralasertib in Combination With Cytotoxic Chemotherapy and/or DNA Damage Repair/Novel Anti-cancer Agents in Patients With Advanced Solid Malignancies.CA, MA, NY, PAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AZD5305PARP1 inhibitorClinical Trials
CeralasertibATR kinase inhibitor AZD6738, AZD6738ATR kinase inhibitorClinical Trials
OlaparibLynparza, AZD2281PARP inhibitorApproved in Ovarian Cancer
NCT01543763IAdvanced solid tumors (in ovarian expansion)Phase I Study to Evaluate the Tolerability, Efficacy, and Safety of Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid TumorsCAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AbexinostatPCI-24781, HDAC inhibitor CRA-024781HDAC inhibitorClinical Trials
PazopanibVotrientMulti-targeted RTK inhibitor
NCT03054298IRecurrent or persistent serous ovarian cancerPhase I Study of Human Chimeric Antigen Receptor Modified T Cells in Patients With Mesothelin Expressing CancersPAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CyclophosphamideSendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, CiclofosfamidaDNA damaging agentApproved in Ovarian Cancer
huCART-meso cellsImmune response against cancer expressing mesothelinClinical Trials
NCT03585764IRecurrent or persistent FRalpha+ high grade serous ovarian cancerPhase I Clinical Trial of Adoptive Transfer of Autologous Folate Receptor - Alpha Redirected T Cells for Recurrent High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal CancerPAView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CyclophosphamideSendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, CiclofosfamidaDNA damaging agentApproved in Ovarian Cancer
FludarabineFludara Oral, 2-F-ara-AMP, BeneflurDNA synthesis inhibitorApproved in Other Cancers
MOv19-BBz CAR TImmune response against cancer expressing folate receptorClinical Trials
NCT03968406IRecurrent ovarian cancer (amenable to radiation therapy) - without ascitesPhase I Study of Talazoparib in Combination With Radiation Therapy for Locally Recurrent Gynecologic CancersTXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Radiation TherapyIrradiation, Radiotherapy
TalazoparibMDV3800, BMN-673, Talazoparib Tosylate, TalzennaPARP inhibitorApproved in Other Cancers
NCT04053673IAdvanced solid tumors with TIPARP amplification (in expansion)A Phase 1, First-in-human Study of the Safety, Single- and Multiple-Dose Pharmacokinetics, and Preliminary Activity of Escalating Doses of RBN-2397, an Oral PARP7 Inhibitor, in Patients With Solid TumorsCO, CT, FL, MA, MO, PA, TN, TXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
RBN-2397PARP7 inhibitorClinical Trials
NCT04092270IRecurrent ovarian cancer (inc expansion)A Phase I/Ib Dose Escalation Study of Pegylated Liposomal Doxorubicin (PLD) With Peposertib (M3814) in Platinum - Resistant or Ineligible Ovarian and Related Cancers With Planned Expansions in High Grade Serous (HGSOC) and Low Grade Serous Ovarian Cancer (LGSOC)CO, GA, MA, NJ, NY, OK, PA, VA, WIView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Liposomal doxorubicinPegylated Liposomal Doxorubicin Hydrochloride, liposomal doxorubicin, LipoDox, Evacet, Dox-SL, DoxilTopoisomerase II inhibitorApproved in Ovarian Cancer
NedisertibM3814, DNA-PK inhibitor MSC2490484A, PeposertibDNA-PK inhibitorClinical Trials
NCT04182516IAdvanced solid tumors (inc ovarian expansion)A Phase I Dose Escalation Study of NMS-03305293 in Adult Patients With Selected Advanced/Metastatic Solid TumorsTXView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
NMS-03305293PARP inhibitorClinical Trials
NCT04249843IAdvanced solid tumors with BRAF mutations Class II: K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, G469S or BRAF fusion or BRAF V600 tumors with progression after prior BRAF inhibitor or MEK inhibitor (in expansion)A First-in-Human, Phase 1a/1b, Open Label, Dose-Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, and Antitumor Activity of the RAF Dimer Inhibitor BGB-3245 in Patients With Advanced or Refractory TumorsCA, LA, MA, NY, TX, VAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
BrimarafenibBGB-3245BRAF kinase inhibitorClinical Trials
NCT04267939IAdvanced solid tumors with DNA Damage Repair pathway alterations, e.g. ARID1A, ATM, ATR, ATRX, BAP1, BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCA , FANCC , FANCD2 , FANCE , FANCF, FANCL, MRE11A, MSH2, NBN, PALB2, PARP1, POLD1, POLE, RAD51, RAD51B, RAD51C, RAD51D, RAD54L or XRCC or CCNE1 AMP (inc ovarian expansion)An Open-label Phase 1b Study to Determine the Maximum Tolerated and/or Recommended Phase 2 Dose of the ATR Inhibitor Elimusertib (BAY 1895344) in Combination With PARP Inhibitor Niraparib, in Participants With Recurrent Advanced Solid Tumors and Ovarian CancerMA, TXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
ElimusertibATR kinase inhibitor BAY1895344, BAY1895344ATR kinase inhibitorClinical Trials
NiraparibZejula, MK4827PARP inhibitorApproved in Ovarian Cancer
NCT04315233IRecurrent serous ovarian cancerA Phase I/Ib Trial of the CDK4/6 Antagonist Ribociclib And The HDAC Inhibitor Belinostat In Patients With Metastatic Triple Negative Breast Cancer And Recurrent Ovarian Cancer With Response Prediction By Genomics (CHARGE)UT, VAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
BelinostatPXD101HDAC inhibitorApproved in Other Cancers
RibociclibKisqali, CDK4/6 Inhibitor LEE011, LEE011, KisqaliCDK4/6 inhibitorApproved in Other Cancers
NCT04329494IRecurrent ovarian cancer with peritoneal diseaseSafety and Efficacy of Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) in Ovarian, Uterine, Appendiceal, Colorectal, and Gastric Cancer Patients With Peritoneal Carcinomatosis (PC)CA, FL, NYView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CisplatinCACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, PlatosinDNA damaging agentApproved in Ovarian Cancer
Doxorubicin14-Hydroxydaunomycin, Hydroxyl-DaunorubicinTopoisomerase II inhibitorApproved in Other Cancers
PIPACpressurized intraperitoneal aerosol chemotherapyClinical Trials
NCT04257110IAdvanced HER2+ solid tumors (in expansion)A First-in-human, Open Label, Multiple Dose, Dose Escalation and Cohort Expansion Phase I Study to Investigate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of BB-1701 in Subjects With Locally Advanced/Metastatic HER2 Expressing Solid TumorsCA, TN, VAView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
BB-1701ADC: anti-HER2 + microtubule destabilizer (eribulin)Clinical Trials
NCT04526106IAdvanced solid tumors with FGFR2 alterations (in expansion)A First-in-human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With Intrahepatic Cholangiocarcinoma (ICC) and Other Advanced Solid TumorsAZ, CA, FL, GA, IL, MA, MI, MN, NY, OH, PA, TX, UT, WAView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
RLY-4008FGFR2 inhibitorClinical Trials
NCT04608409IPartially platinum sensitive, platinum resistant or refractory ovarian cancerA Phase I Dose-Escalation Study on the Safety of Lapatinib With Dose-Dense Paclitaxel in Patients With Platinum-Resistant Ovarian CancerKYView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
LapatinibGW2016, GSK572016, lapatinib ditosylate, TykerbEGFR and HER2 kinase inhibitorApproved in Other Cancers
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitorApproved in Ovarian Cancer
NCT04044859IAdvanced MAGE-A4+ solid tumors (in expansion)A Phase 1 Dose Escalation Study To Assess Safety And Efficacy Of ADP-A2M4CD8 As Monotherapy Or In Combination With Either Nivolumab Or Pembrolizumab In HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)FL, MA, MO, NY, NC, OK, TN, TX, WIView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
ADP-A2M4CD8SPEAR T-cell ADP-A2M4CD8, autologous genetically-modified MAGE-A4 C1032 CD8alpha T cellsImmune response against cancer expressing MAGE-A4Clinical Trials
NCT04673448IRecurrent ovarian cancer with BRCA1/2 mutationsPhase IB Trial of Niraparib and TSR-042 in Patients With BRCA-Mutated Breast, Pancreas or Ovary CancerWAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
DostarlimabTSR-042, anti-PD-1 monoclonal antibody TSR-042, ANB011Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NiraparibZejula, MK4827PARP inhibitorApproved in Ovarian Cancer
NCT04703920IRecurrent high grade serous ovarian cancerA Phase 1 Dose-Escalation Trial of Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian CancerMIView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
BelinostatPXD101HDAC inhibitorApproved in Other Cancers
TalazoparibMDV3800, BMN-673, Talazoparib Tosylate, TalzennaPARP inhibitorApproved in Other Cancers
NCT04707248IRecurrent ovarian cancer (in expansion)Phase I, Two-Part, Multi-Center, First-in-Human Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian TumorsAZ, CO, FL, OK, TNView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Raludotatug deruxtecanDS-6000aADC: anti-CDH6 + topoisomerase I inhibitor (Dxd)Clinical Trials
NCT04718675IRecurrent ovarian cancer with MYC overexpression or MYC amplification (inc expansion)Phase 1, First-in-human, Open-label Dose Escalation and Cohort Expansion Study of KB-0742 in Patients With Relapsed or Refractory Solid Tumors or Non-Hodgkin LymphomaCA, IN, MA, MI, MO, PA, TN, TX, VAView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
KB-0742CDK9 inhibitorClinical Trials
NCT04890613IOvarian cancer with germline BRCA2 or germline PALB2 alterations, or high grade serous or endometrioid ovarian cancer with BRCA1 alterations or other HRD-associated mutationsPhase Ib Expansion Study of CX-5461 in Patients With Solid Tumours and BRCA2 and/or PALB2 MutationCA, FL, MA, OH, PAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
PidnarulexPol I inhibitor CX5461, RNA Pol I inhibitor CX5461, CX-5461Pol I inhibitorClinical Trials
NCT05057715IPersistent or recurrent serous ovarian cancerPhase 1 Trial of Human Chimeric Antigen Receptor Modified T Cells (huCART-meso) Administered in Combination With VCN-01 in Patients With Pancreatic and Serous Epithelial Ovarian CancerPAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
huCART-meso cellsImmune response against cancer expressing mesothelinClinical Trials
VCN-01PH20 hyaluronidase-expressing adenovirus VCN-01Induces immune response and tumor cell lysisClinical Trials
NCT05216432IAdvanced solid tumors (inc ovarian expansion)A First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination With Fulvestrant in Patients With Advanced Breast CancerAZ, CO, FL, MA, NY, TN, TX, VA, WIView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
RLY-2608PI3K alpha inhibitorClinical Trials
NCT05229900IAdvanced solid tumors (inc ovarian expansion)A Phase 1 Study of SGN-ALPV in Advanced Solid TumorsCA, CT, FL, MI, OK, UT, VAView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
SGN-ALPVADC: anti-ALPP + microtubule destabilizer (MMAE)Clinical Trials
NCT05238831IRecurrent ovarian cancerSerial Measurements of Molecular and Architectural Responses to Therapy (SMMART) Trial: Adaptive Clinical Treatment (ACT)ORView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AlectinibAF802, anaplastic lymphoma kinase inhibitor CH5424802, Alecensa, ALK inhibitor CH5424802ALK kinase inhibitorApproved in Other Cancers
AlpelisibPI3K inhibitor BYL719, BYL719, phosphoinositide 3-Kinase inhibitor BYL719, PiqrayPI3K alpha inhibitorApproved in Other Cancers
AnastrozoleArimidexAromatase inhibitor
AtezolizumabTecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446Blocks PD-L1 inhibition of T cellsApproved in Other Cancers
Bevacizumabimmunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, AvastinVEGF antagonistApproved in Ovarian Cancer
CapecitabineCAPE, XelodaRNA processing and thymidylate synthase inhibitorNCCN Guidelines for Ovarian Cancer
CarboplatinParaplatin, NovoplatinumDNA damaging agentApproved in Ovarian Cancer
CobimetinibXL518, GDC-0973, CotellicMEK1 inhibitorApproved in Other Cancers
EntrectinibRXDX-101, TrkA/B/C/ROS1/ALK tyrosine kinase inhibitor RXDX-101, RozlytrekALK, TRK, ROS1 kinase inhibitorApproved in Other Cancers
EribulinB1939 mesylate, E7389, ER-086526, Halaven, halichrondrin B analogMicrotubule destabilizer/mitotic inhibitorApproved in Other Cancers
FulvestrantZD9238, ICI 182,780, FaslodexER antagonist (SERD)Approved in Other Cancers
IrinotecanCampothecin-11, Campto, CamptosarTopoisomerase I inhibitorNCCN Guidelines for Ovarian Cancer
LetrozoleFemaraAromatase inhibitorNCCN Guidelines for Ovarian Cancer
nab-PaclitaxelPaclitaxel Albumin-Stabilized Nanoparticle Formula, Abraxane, ABI-007Microtubule stabilizer/mitotic inhibitorNCCN Guidelines for Ovarian Cancer
NiraparibZejula, MK4827PARP inhibitorApproved in Ovarian Cancer
OlaparibLynparza, AZD2281PARP inhibitorApproved in Ovarian Cancer
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitorApproved in Ovarian Cancer
PalbociclibPD-0332991, PD0332991, IbranceCDK4/6 inhibitorApproved in Other Cancers
PertuzumabPerjeta, monoclonal antibody 2C4, rhuMAb2C4HER2 dimerization inhibitorApproved in Other Cancers
TrastuzumabHerceptin, Anti-erbB2 Monoclonal Antibody, HER2 Monoclonal AntibodyHER2 antagonistApproved in Other Cancers
Trastuzumab emtansinetrastuzumab-MCC-DM1 immunoconjugate, trastuzumab-MCC-DM1 antibody-drug conjugate, trastuzumab-MCC-DM1, trastuzumab-DM1, T-DM1, Kadcyla, ado trastuzumab emtansineADC: anti-HER2 + microtubule destabilizer (DM1)Approved in Other Cancers
VemurafenibRO5185426, PLX4032, ZelborafBRAF kinase inhibitorApproved in Other Cancers
VinorelbineBiovelbin, Eunades, Navelbine, Navelbine ditartrate, NVB, Vinorelbine tartrate, VNB, Vinorelbine ditartrateMicrotubule destabilizer/mitotic inhibitor
VismodegibHedgehog antagonist GDC-0449, Erivedge, GDC-0449Smoothened antagonistApproved in Other Cancers
NCT05238922IAdvanced solid tumors (inc ovarian expansion)A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid TumorsCA, CO, CT, GA, NY, NC, PA, TXView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
INCB123667CDK2 inhibitorClinical Trials
NCT05271318IRecurrent ovarian cancerA Phase I Open-Label, Dose-escalation Trial of Tumor Necrosis Factor Alpha and Interleukin-2 Coding Oncolytic Adenovirus (TILT-123) in Combination With Pembrolizumab in Patients With Platinum Resistant or Refractory Ovarian CancerMNView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Igrelimogene litadenorepvecTNFalpha/IL-2-encoding oncolytic adenovirus TILT-123, Ad5/3-E2F-d24-hTNFa-IRES-hIL2, TILT-123Induces immune response and tumor cell lysisClinical Trials
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT05300048IAdvanced solid tumors with PIK3CA mutations (inc ovarian expansion)A Phase 1b Study of Serabelisib in Combination With an Insulin Suppressing Diet (Study ISD) and With or Without Nab-paclitaxel in Adult Subjects With Advanced Solid Tumors With PIK3CA Mutations With or Without PTEN LossAL, CA, IN, MN, NJ, NY, NC, PA, SD, TX, WIView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
nab-PaclitaxelPaclitaxel Albumin-Stabilized Nanoparticle Formula, Abraxane, ABI-007Microtubule stabilizer/mitotic inhibitorNCCN Guidelines for Ovarian Cancer
SerabelisibPI3K alpha inhibitor MLN1117, TAK-117, INK-1117, MLN1117PI3K alpha inhibitorClinical Trials
NCT03448042IAdvanced HER2+ solid tumors (in expansion)A Phase Ia/Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of Runimotamab Administered Intravenously as a Single Agent and in Combination With Trastuzumab in Patients With Locally Advanced or Metastatic HER2-Expressing CancersNY, TNView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
RunimotamabBTRC 4017A, anti-HER2 x anti-CD3 bispecific monoclonal antibody BTRC 4017ARe-directs T cells to attack HER2+ tumor cellsClinical Trials
TrastuzumabHerceptin, Anti-erbB2 Monoclonal Antibody, HER2 Monoclonal AntibodyHER2 antagonistApproved in Other Cancers
NCT05360680IAdvanced WT-1+ solid tumors (inc ovarian expansion)A Phase 1, Open-Label, Dose Escalation and Expansion Study of CUE-102 Monotherapy in HLA-A*0201 Positive Patients With WT1 Positive Recurrent/Metastatic CancersAZ, CA, FL, GA, MD, MN, NJ, NY, NC, OH, TX, WA, WIView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CUE-102WT1-targeted IL-2-based fusion protein CUE-102Immune response against cancer expressing WT1Clinical Trials
NCT05417594IRecurrent ovarian with cancer with a BRCA1/2, PALB2 or RAD51C/D alteration (at most 1 prior PARP inhibitor therapy)A Modular Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies (CERTIS1)CA, IL, MA, NY, OR, TXView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AZD9574PARP1 inhibitorClinical Trials
NCT05527184IRecurrent high grade serous ovarian cancer (inc expansion)A Phase 1, First-in-Human, Open-Label, Dose-Escalation and Expansion Study of IMGN151 (Anti-FRα Antibody-drug Conjugate) in Adult Patients With Recurrent Endometrial Cancer and Recurrent, High-Grade Serous Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube CancersCA, CO, FL, OK, TN, TXView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
IMGN151ADC: anti-FRalpha + microtubule destabilizer (DM21)Clinical Trials
NCT03401385IAdvanced solid tumors (in expansion)Phase 1, Two-part, Multicenter, Open-label, Multiple Dose, First-in-human Study of DS-1062a in Subjects With Advanced Solid Tumors (TROPION-PanTumor01)CA, DC, GA, MD, MA, NY, TN, TX, VAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Datopotamab deruxtecanAnti-TROP2/DXd antibody-drug conjugate DS-1062a, Dato-DXdADC: anti-TROP2 + topoisomerase I inhibitor (Dxd)Clinical Trials
NCT03745326IAdvanced solid tumors with a RAS G12D mutationA Phase I/II Study Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 PatientsMDView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AldesleukinIL-2R agonistApproved in Other Cancers
Anti-KRAS G12D mTCR PBLImmune response against cancer expressing RAS G12DClinical Trials
CyclophosphamideSendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, CiclofosfamidaDNA damaging agentApproved in Ovarian Cancer
FludarabineFludara Oral, 2-F-ara-AMP, BeneflurDNA synthesis inhibitorApproved in Other Cancers
NCT05708924IRecurrent ovarian cancer - intraperitoneal infusionMT2021-27 Intraperitoneal FT538 With Intravenous Enoblituzumab in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal CancerMNView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Enoblituzumabmab MGA271, MGA271Immune response against cancer expressing B7H3Clinical Trials
FT538iPSC-derived CD16/IL-15RF-expressing CD38-eliminated NK Cells FT538Anti-tumor immune responseClinical Trials
NCT05787587IRecurrent HRD+ ovarian cancer and advanced solid tumors with alterations in ATM, BARD1, BRCA1/2, BRIP1, CDK12, CHEK1/2, FANCA/L, NBN, PALB2, PPP2R2A, RAD51B/C/D, RAD54L or high LOH or HRD+ (in ovarian expansion)A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid TumorsCO, OK, PA, TN, TX, UT, VAView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
IDE161PARG inhibitorClinical Trials
NCT05950464IRecurrent clear cell or endometrioid ovarian cancer or platinum resistant high grade serous ovarian cancer (inc ovarian expansion)A Phase 1B Study of Combination ATR (M1774) and BET Inhibition (ZEN00-3694) to Exploit ARID1A Loss in Recurrent Ovarian and Endometrial CancerPAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
TuvusertibATR kinase inhibitor M1774, M1774ATR kinase inhibitorClinical Trials
ZEN-3694ZEN003694, BET bromodomain inhibitor ZEN-3694BET inhibitorClinical Trials
NCT05989724IAdvanced solid tumors (inc ovarian expansion)A First-in-Human (FIH), Open-Label, Phase Ia/Ib Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SON-DP in Participants With Relapsed/Metastatic Solid TumorsAZ, MI, NC, OK, TXView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
SON-DPUndisclosed mechanismClinical Trials
NCT04847063INewly diagnosed or recurrent ovarian cancer with peritoneal diseaseIndividualized Response Assessment to Heated Intraperitoneal Chemotherapy (HIPEC) for the Treatment of Peritoneal Carcinomatosis From Ovarian, Colorectal, Appendiceal, or Peritoneal Mesothelioma HistologiesMDView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CisplatinCACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, PlatosinDNA damaging agentApproved in Ovarian Cancer
Doxorubicin14-Hydroxydaunomycin, Hydroxyl-DaunorubicinTopoisomerase II inhibitorApproved in Other Cancers
HIPECHyperthermic Intraperitoneal ChemotherapyNCCN Guidelines for Ovarian Cancer
OxaliplatinOHP, Eloxatine, Dacplat, Dacotin, EloxatinDNA damaging agent
SurgeryClinical Trials
NCT05039801IAdvanced solid tumors with KEAP1, NF1, NFE2L2, or STK11 (LKB1) alterations, or platinum resistant or refractory high grade serous ovarian cancer with low expression of ASNS, or recurrent clear cell ovarian cancer with an ARID1A mutation or platinum resistant or refractory high grade ovarian cancer (combo w/ paclitaxel and bevacizumab) (inc expansion)A Phase 1 Open-Label, Dose-Escalation and Dose-Expansion Study to Investigate the Safety, Pharmacokinetics, and Anti-Tumor Activity of IACS-6274 as Monotherapy and in Combination in Patients With Advanced Solid TumorsTXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Bevacizumabimmunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, AvastinVEGF antagonistApproved in Ovarian Cancer
IACS-6274glutaminase inhibitor IPN60090, IPN60090Glutaminase inhibitorClinical Trials
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitorApproved in Ovarian Cancer

If you have any questions or would like help with your search, please call us at: 858-657-0282 or email us at patientsupport@clearityfoundation.org.